A 42-year-old woman from Delhi presents with a 6-month history of recurrent epigastric pain, early satiety, and occasional hematemesis. Upper endoscopy reveals a gastric ulcer with a clean base. Rapid urease test on antral biopsy is positive. Which of the following best describes the pathogenic mechanism and the rationale for triple therapy in this patient?

Explanation

## Helicobacter pylori Infection & Peptic Ulcer Disease ### Organism Identification & Pathogenesis **Key Point:** Helicobacter pylori is a microaerophilic, gram-negative, spiral-shaped bacterium that colonizes the gastric mucosa and is the leading cause of peptic ulcer disease worldwide (>90% of duodenal ulcers, ~70% of gastric ulcers). ### Virulence Mechanisms | Mechanism | Function | Clinical Consequence | |-----------|----------|---------------------| | **Urease enzyme** | Hydrolyzes urea → ammonia + CO₂; neutralizes gastric acid in immediate vicinity | Enables survival in acidic gastric environment; allows colonization of mucosa | | **Flagella** | Motility through viscous mucus layer | Penetration to deeper epithelium | | **Adhesins (BabA, SabA)** | Bind to Lewis antigen on gastric epithelium | Intimate mucosal attachment | | **Cytotoxin-associated antigen A (CagA)** | Injected via type IV secretion system; phosphorylated in host cells | Disrupts tight junctions; increases gastric acid secretion; pro-inflammatory | | **Vacuolating cytotoxin A (VacA)** | Produces intracellular vacuoles in epithelial cells | Epithelial damage and apoptosis | **High-Yield:** Urease is the most important virulence factor—it is the basis for rapid urease test (RUT) diagnosis and explains why H. pylori cannot survive in non-gastric acidic environments. ### Diagnostic Approach **Clinical Pearl:** Rapid urease test (RUT) on antral biopsy is positive within 1 hour due to the high urease activity of H. pylori. Sensitivity ~95%, specificity ~98%. **Mnemonic:** CHOP = **C**agA, **H**elicase (flagella), **O**uter membrane proteins (adhesins), **P**roton pump (urease) ### Triple Therapy Rationale ```mermaid flowchart TD A["H. pylori infection confirmed"]:::outcome --> B["Triple therapy initiated"]:::action B --> C["PPI: Omeprazole/Pantoprazole"]:::action B --> D["Antibiotic 1: Amoxicillin"]:::action B --> E["Antibiotic 2: Clarithromycin"]:::action C --> F["↓ Gastric acid secretion"]:::outcome F --> G["Ulcer healing"]:::outcome D --> H["Cell wall synthesis inhibition"]:::outcome E --> I["Protein synthesis inhibition"]:::outcome H --> J["Bacterial eradication"]:::outcome I --> J J --> K["Ulcer recurrence prevention"]:::outcome ``` **Key Point:** Triple therapy (PPI + two antibiotics) achieves eradication rates of 85–95% when compliance is good. The PPI serves dual purposes: 1. **Acid suppression** — promotes ulcer healing by reducing acid-pepsin activity 2. **Antibiotic optimization** — creates a less acidic environment, improving antibiotic penetration and activity ### Treatment Duration & Monitoring - Standard duration: 7–14 days (varies by region and resistance patterns) - Test-of-cure: Perform urea breath test (UBT) or stool antigen test ≥4 weeks after therapy completion - Avoid repeat RUT immediately after therapy (false negatives due to achlorhydria from PPI) **Clinical Pearl:** In India and other regions with high clarithromycin resistance, quadruple therapy (PPI + bismuth + tetracycline + metronidazole) or sequential therapy may be preferred as first-line. ### Complications of Untreated H. pylori - Chronic atrophic gastritis → intestinal metaplasia → gastric adenocarcinoma (intestinal type) - MALT lymphoma (mucosa-associated lymphoid tissue) - Refractory peptic ulcer disease - Pernicious anemia (vitamin B₁₂ malabsorption in atrophic gastritis)